ISPOR Europe | Nov 17-20, 2024

ClearNote Health presented findings from a clinico-economic analysis of its Avantect Pancreatic Test in a poster entitled “Cell-Free DNA Epigenomic-based Test is Predicted to Be Cost Effective to Manage New-Onset Type 2 Diabetes Patients for Risk of Pancreatic Cancer” (abstract #141003)